Female Pattern Hair Loss · FUE · DHI · Ludwig I–III

Female Hair Transplant in Turkey — FUE & DHI for Women at Eyeglow Istanbul

FUE (sapphire blade, 0.7–0.8 mm punch) and DHI (Choi pen, unshaven option) for female pattern hair loss, androgenetic alopecia and temporal recession. Mandatory hormonal screening before surgery — PCOS, thyroid, ferritin and androgen profile assessed pre-operatively. Performed at our partner accredited hair clinic by a board-certified hair restoration surgeon. Written graft estimate and one year of structured photographic aftercare.

Get a written graft estimate Compare with DHI

Female hair transplant at Eyeglow, Istanbul

Primary techniquesFUE (preferred) · DHI (unshaven option)

AnaesthesiaLocal + light sedation

Typical graft range1,500–2,500 grafts

Long hair optionDHI under 2,500 grafts

Time in Istanbul3–4 nights

Final result12–18 months

Verified across global platforms.

Real patient reviews, openly listed worldwide.

What it is

What is female hair transplant?

Female hair transplant is a surgical procedure that transfers permanent, DHT-resistant hair follicles from the occipital donor zone to thinned or bald areas — primarily the frontal hairline, temporal recession zones and widening crown part — in women with female pattern hair loss (FPHL) or androgenetic alopecia. Two techniques are used: FUE with sapphire blade (preferred for most cases) and DHI with Choi implanter pen (preferred when an unshaven recipient option is required).

At Eyeglow Health in Istanbul, female hair transplant is coordinated with our partner accredited hair restoration clinic. The operating surgeon is a partner specialist; Eyeglow provides the coordinator, assessment framework and structured aftercare throughout the 12-month follow-up period. We are transparent that Eyeglow is an eye-care specialist clinic — hair restoration is delivered through our accredited partner clinic network with full clinical disclosure.

Female hair loss assessment is fundamentally different from male assessment. A mandatory pre-operative hormonal blood panel (CBC, ferritin, TSH, androgen profile) rules out reversible causes. Trichoscopy of the donor zone confirms whether the occipital band contains stable, non-miniaturised follicles. Approximately one in four women who request a female hair transplant consultation at Eyeglow are directed toward medical optimisation first — surgery on an unstabilised or insufficiently evaluated loss pattern produces inferior and potentially short-lived results. That honest assessment is the foundation of our female consultation process.

How it works

From hormonal screening to recovery at home

01
Online consultation + hormonal screening checklist
You share four standardised photographs (frontal hairline, top-of-crown, left temporal, right temporal), your hair-loss history, current medications and any available blood test results. Female hair loss has significantly more possible causes than male pattern baldness — hormonal imbalance (PCOS, thyroid, elevated androgens), iron/ferritin deficiency, telogen effluvium and post-menopausal androgenetic alopecia must be assessed before any surgical plan is made. Our hair surgeon reviews your case, determines the likely cause pattern and provides a checklist of pre-operative blood tests required before a graft estimate can be issued.
02
Hormonal and medical pre-operative optimisation
Required pre-op blood tests: CBC + ferritin + iron saturation (rule out deficiency anaemia), TSH + free T4 (thyroid function), DHEA-S + testosterone + SHBG (androgen profile), FSH + LH + oestradiol if peri/post-menopausal, prolactin if irregular cycles, INR + hepatitis B/C + HIV per Turkish Ministry of Health protocol. If results indicate reversible or partially reversible hair loss (e.g. low ferritin, undertreated thyroid, early PCOS), medical optimisation (minoxidil 2–5%, spironolactone, iron supplementation, thyroid management) is recommended for 3 to 6 months before surgery to stabilise the loss pattern and maximise donor yield. We are honest that not every woman presenting with diffuse thinning is a transplant candidate: surgery on an unstabilised active loss pattern carries a meaningful risk of continued post-transplant loss of surrounding native hair.
03
Pre-operative assessment in Istanbul
Day 1 in Istanbul: trichoscopy (dermoscopy assessment of scalp) + hair pull test + hair density measurement at frontal, temporal, crown and donor zones using a folliscope or digital trichoscope. The donor zone in women is the lower occipital band — typically narrower and less dense than in men, and potentially affected by diffuse thinning. The hair surgeon assesses donor zone miniaturisation under dermoscopy. If the donor zone shows significant miniaturisation (indicating diffuse unpatterned alopecia, DUPA), surgery may not be appropriate regardless of how the frontal zone looks. Hairline design, zone priority mapping and graft count plan are finalised at this visit.
04
Technique selection — FUE or DHI (women-specific factors)
FUE with sapphire blade (0.7–0.8 mm punch) is the preferred technique for most female cases: efficient donor area extraction, precise channel creation for dense packing of temporal and frontal zones, and the ability to handle 2,000 to 3,000+ grafts in a single session. DHI (Choi implanter pen) is offered as an alternative when the unshaven recipient option is clinically appropriate — DHI allows the existing hair to remain in place in the recipient zone, so the patient can return to social or professional environments immediately after the procedure. DHI adds surgical complexity when long hair is present in the recipient zone and may increase procedure time. The choice is made case-by-case based on graft count, donor density, patient preference for the recovery period and the surgeon's clinical assessment.
05
Procedure day (6–9 hours)
Donor area (lower occipital band) is shaved to a short stubble for graft extraction. If DHI is selected, the recipient zone may remain unshaven for sessions under 2,500 grafts. Local anaesthetic with light intravenous sedation. FUE: sapphire blade micro-punches (0.7–0.8 mm) extract follicular units individually; recipient channels are pre-created with sapphire-tipped blades for precise angle and depth control; grafts placed with forceps. DHI: grafts extracted with micropunches then loaded directly into Choi implanter pens for single-step channel + implantation. Dense packing is prioritised in the frontal hairline and temporal recession zones — the highest-visibility areas in female pattern hair loss (Ludwig I to III).
06
Recovery and one-year structured aftercare
Day 1 wash with antiseptic solution at the clinic. Redness and mild swelling for 3 to 7 days. Shock loss (temporary shedding of grafts and surrounding native hair) between weeks 2 and 8 is normal and expected. First new growth at 3 to 4 months; 50–60 percent density by month 6; final result at 12 to 18 months. Minoxidil 2–5% (or 5% if tolerated) and any medically appropriate concurrent medical therapy are continued through the growth phase. Photographic review at 1, 3, 6 and 12 months by video consultation with our hair coordinator.

Partner clinic network

How Eyeglow coordinates female hair restoration

Eyeglow Health's clinical specialism is eye surgery and vision care — our founding physicians are ophthalmologists. Hair restoration is outside our core surgical specialism. Rather than offering hair transplant under our own roof with a general surgeon, we have built a partner clinic network with accredited hair restoration clinics in Istanbul that hold the Turkish Ministry of Health International Health Tourism Authority Certificate.

For your female hair transplant: the operating surgeon is a partner specialist with documented FUE and DHI volume in female patients specifically. Eyeglow is responsible for your coordinator (single named contact from first message to 12-month review), the assessment framework (hormonal screening protocol, trichoscopy requirements, candidacy criteria), the package structure (hotel, transfers, complication insurance, aftercare programme) and your experience in Istanbul. The surgical procedure takes place at the partner clinic with the partner surgical team.

This model is disclosed transparently in every consultation. We believe that specialist surgeons performing procedures in their documented domain — rather than general tourism clinics where the same team operates on eyes, hair and teeth — produce better outcomes for patients.

Treatment options

Female FUE vs DHI vs PRP vs Medical (minoxidil + oral)

The right treatment for female hair loss depends on the cause, the degree of donor zone health, the urgency of restoration and whether the loss is still active or stabilised. Here is how the four main options compare:

Aspect	FUE (sapphire)	DHI (Choi pen)	PRP + Mesotherapy	Minoxidil + oral medical
Technique	FUE — sapphire blade, separate channel + implant	DHI — Choi pen, channel + graft in one motion	PRP + Mesotherapy — injectable, non-surgical	Minoxidil + oral medical — topical/systemic
Graft range (women)	1,500–3,500+ grafts (any size)	1,500–2,500 grafts (medium sessions)	Not a transplant — no graft extraction	Not a transplant — stimulates existing follicles
Unshaven recipient	Limited (partial shaving)	Possible under 2,500 grafts	Always unshaven	Always unshaven
Best female indication	Ludwig I–III, temporal recession, frontal thinning	Frontal/temporal with unshaven priority	Early diffuse thinning, post-op adjunct, maintenance	Active loss stabilisation, pre/post-op optimisation
Procedure time	6–9 hours	7–10 hours	60–90 minutes (per session)	Ongoing daily/weekly
Downtime	7–10 days crusts	5–10 days crusts	Same day (mild redness)	None (scalp irritation possible)
Permanent result	Yes — transplanted grafts are DHT-resistant	Yes — transplanted grafts are DHT-resistant	No — maintenance sessions needed	No — benefit lost if discontinued

Pricing

Personalised pricing

Every treatment plan is priced individually after your consultation. Request a written, all-inclusive quote — clear, itemised, and with no obligation.

Request a written quote

Package transparency

What's included in your female hair transplant package

Included in package

Pre-op consultation + trichoscopy + donor density measurement
Hair surgeon-led hairline design + zone priority + graft count plan
Blood tests (CBC, ferritin, TSH, androgen profile, INR, hepatitis B/C, HIV — Turkish Ministry of Health protocol)
FUE procedure with sapphire blade 0.7–0.8 mm punch + dense packing temporal/frontal OR DHI with Choi pen (technique confirmed at consultation)
Local anaesthetic + light intravenous sedation
5-star hotel — 3 nights
VIP airport transfers (return)
All post-op medications + special shampoo + lotion + aftercare kit
First wash at the clinic + post-op counselling
1, 3, 6 and 12-month photographic video follow-up
Multilingual hair coordinator — 24/7
Complication insurance policy (Türkiye Ministry of Health certified, covers surgical complications including infection, retreatment, and emergency intervention up to package value)

Paid separately

Items below are not part of the medical package — your coordinator helps you arrange them at no markup.

Flights to/from Istanbul
Personal expenses
Pre-op blood tests (where not performed in Istanbul — many patients obtain these at home before travel)
Minoxidil 2–5% topical (continued at home — some brands available in Istanbul pharmacy)
Oral spironolactone or finasteride if prescribed (prescription only)
PRP / Mesotherapy sessions if added as adjunct (quoted separately)
Second-session top-up (quoted separately after 12-month review)
Hormonal or thyroid management (with your local physician)
Travel insurance (recommended — covers flight cancellation, baggage, non-surgical medical emergencies abroad; we coordinate referral if needed)

Candidacy

Are you a candidate for female hair transplant?

You may be a candidate if

You have female pattern hair loss (androgenetic alopecia, FPHL) at Ludwig scale I, II or III — stable for at least 12 months with or without medical therapy.
Your donor zone (lower occipital band) has adequate density without significant miniaturisation confirmed by trichoscopy.
Pre-operative blood panel shows no active hormonal, nutritional or systemic cause that can be reversed before surgery.
You want to restore frontal hairline density, address temporal recession or fill in a widening part — the highest-visibility zones in female hair loss.
You are not pregnant or breastfeeding, and are not planning pregnancy within 12 months of the procedure (hormonal shifts during/after pregnancy affect the result).

Medical optimisation first may be the right step if

You have diffuse unpatterned alopecia (DUPA) — diffuse thinning throughout the entire scalp including the donor zone. In DUPA the donor area is not a stable source of DHT-resistant grafts; transplanted hair may continue to miniaturise post-surgery. This is the most important contraindication unique to female candidates and it can only be confirmed by trichoscopy in Istanbul.
You have active hormonal imbalance (untreated PCOS, undertreated thyroid disease, low ferritin) that is driving the hair loss. In this case medical optimisation for 3 to 6 months before reconsidering surgery is the correct sequence — not skipping to transplant.
You are currently pregnant or breastfeeding — surgery is contraindicated.
You are in active telogen effluvium (diffuse shedding from a recent trigger — post-partum, crash diet, major illness, surgery). Wait for shedding to stabilise for 6 to 12 months.
Your hair loss started in the last 6 to 12 months and the progression pattern is not yet clear. Transplanting into an unstabilised loss pattern risks continued thinning of native hair around the transplanted zone.

Disclaimer. Information on this page is consistent with International Society of Hair Restoration Surgery (ISHRS) practice standards, American Hair Loss Association (AHLA) guidelines on female hair loss and Turkish Ministry of Health International Health Tourism Authority Certificate requirements. Candidacy for female hair transplant requires individual trichoscopic and hormonal assessment — this page describes general criteria only. A written graft estimate will not be issued at Eyeglow Health without confirmation of donor zone health and pre-operative blood panel review.

Risks & outcomes

Realistic outcomes — the risks that actually matter in female hair transplant

Female hair transplant has a distinct risk profile from male transplant. We list the female-specific risks here in the same plain language our hair surgeon uses in your consultation:

Donor zone thinning (female-specific)

In female pattern hair loss the donor zone (lower occipital band) is narrower and may itself be affected by diffuse thinning — unlike male pattern baldness where the donor zone is typically stable. Extracting from a thinning donor zone creates visible cosmetic gaps in an area that women often wear down or in a bun. Trichoscopy and dermoscopic miniaturisation assessment of the donor zone is non-negotiable in female consultations. We do not issue a graft estimate until donor zone health is confirmed.

Post-transplant native hair loss

The transplanted grafts are DHT-resistant and will grow permanently. However, surrounding native (non-transplanted) hair may continue to thin in women with active androgenetic alopecia or insufficiently controlled hormonal causes. A successful transplant result at month 12 can be partially offset by continued thinning of untransplanted zones at month 36 to 48. This is why concurrent minoxidil, medical therapy and hormonal management are part of the post-op protocol — not optional extras.

Shock loss of existing hair

Temporary shedding of transplanted grafts and surrounding native hair (shock loss) between weeks 2 and 8 is normal and expected after any hair transplant procedure. For women with diffuse thinning who have limited existing density to begin with, the shock loss phase can be distressing as hair appears thinner than before surgery for a period of 6 to 10 weeks. This resolves as regrowth begins at 3 to 4 months. We describe this process in detail before any procedure is booked so it is not a surprise.

Unshaven DHI complications in longer hair

DHI allows the recipient zone to remain unshaven for sessions under 2,500 grafts, which is socially important for many women. However, existing long hair in the recipient area increases surgical complexity — the surgeon must navigate around existing strands to create channels and implant grafts precisely. This may slightly increase procedure time and graft trauma risk. For sessions over 2,500 grafts, full recipient shaving is recommended to maintain precision. We discuss this honestly so the patient chooses the technique that fits both her clinical picture and her social recovery needs.

FAQ

Frequently asked questions about female hair transplant

Is female hair transplant different from male hair transplant?

Yes — significantly. Female hair loss (FPHL, androgenetic alopecia in women) is typically diffuse rather than patterned like male Norwood baldness. This creates two female-specific challenges that do not apply to most men: (1) the donor zone (lower occipital band) may itself be affected by diffuse thinning — trichoscopy and miniaturisation assessment of the donor zone is essential before any graft estimate; (2) the cause of hair loss is more varied in women (hormonal: PCOS, thyroid, androgens; nutritional: low ferritin; metabolic; autoimmune), so a mandatory pre-operative hormonal blood panel is required to rule out reversible causes before surgery. A hair transplant in a woman with uncontrolled hormonal hair loss will produce a cosmetically inferior and potentially short-lived result. The technique used (FUE or DHI) is the same as for men, but the assessment pathway, the candidacy criteria and the surgical planning are substantially different.

What is the success rate of female hair transplant?

In appropriately selected candidates — stable FPHL at Ludwig I to III, adequate donor density without miniaturisation confirmed by trichoscopy, pre-op blood panel without active hormonal or nutritional deficiency — graft survival rates of 90 to 95 percent are published in the ISHRS literature, comparable to male hair transplant outcomes. The key qualifier is "appropriately selected candidates": women with diffuse unpatterned alopecia (DUPA), active hormonal causes or inadequate donor zone density have significantly lower expected outcomes. We are honest in female consultation: if trichoscopy shows donor zone miniaturisation above 20 percent, we do not proceed with surgery.

Can I keep my long hair during a female hair transplant?

Partially — it depends on the technique and graft count. DHI (Choi implanter pen) allows the recipient zone to remain unshaven for sessions under 2,500 grafts; the existing hair in the recipient area stays in place while the surgeon navigates around it. The donor zone (lower occipital band) must be shaved regardless of technique, because the surgeon needs to see individual follicular units for extraction. Many women with long hair choose DHI specifically to avoid the shaved donor patch being visible, covering it with the remaining hair length. For FUE, partial shaving strategies (leaving a thin strip of hair over the shaved donor area) are sometimes used for social reasons but add surgical complexity. We discuss the specific options based on your hair length and the planned graft count at consultation.

Does hormonal cause screening need to happen before a female hair transplant?

Yes — this is non-negotiable at Eyeglow Health. The required pre-operative blood panel includes CBC + ferritin + iron saturation (rule out deficiency anaemia), TSH + free T4 (thyroid function), DHEA-S + testosterone + SHBG (androgen profile), FSH + LH + oestradiol if peri/post-menopausal, prolactin if irregular menstrual cycles. Correctable causes — low ferritin, undertreated thyroid, elevated androgens in PCOS — should be medically optimised for 3 to 6 months before hair transplant to stabilise the loss pattern, improve the donor zone environment and maximise the durability of the transplanted result. A graft estimate cannot be issued before the blood panel is reviewed.

Can women with PCOS have a hair transplant?

Yes — many women with PCOS undergo successful hair transplant after appropriate pre-operative medical optimisation. PCOS-related androgenetic alopecia responds to anti-androgen therapy (spironolactone, combined oral contraceptive) and/or minoxidil. If androgen levels are controlled and hair loss is stabilised for 12+ months, surgical restoration of the frontal hairline and temporal zones is clinically appropriate for candidates with adequate donor density. If PCOS is poorly controlled and hair loss is still actively progressing, surgery before stabilisation carries significant risk of continued post-transplant native hair loss. We assess this case-by-case using the pre-operative hormonal panel.

Is PRP recommended alongside a female hair transplant?

PRP (platelet-rich plasma) and mesotherapy are commonly used as adjuncts to female hair transplant at our partner accredited hair clinic. PRP is rich in growth factors (PDGF, VEGF, TGF-beta) that support graft survival in the early post-operative phase and stimulate surrounding native follicles in the months following transplant. Published evidence supports PRP as an adjunct that may improve graft take and accelerate the early growth phase, though it does not replace appropriate hormonal management or minoxidil therapy. A typical adjunct programme for female patients is 3 PRP sessions in the 12 months post-transplant. Whether PRP is included in your package or quoted separately depends on your consultation outcome.

What is diffuse unpatterned alopecia (DUPA) and why does it affect candidacy?

Diffuse unpatterned alopecia (DUPA) is a form of androgenetic alopecia where miniaturisation (progressive DHT-related follicle shrinkage) affects the entire scalp — including the occipital and parietal zones normally used as the donor area in hair transplantation. In standard male or female pattern baldness, the donor zone is assumed to contain DHT-resistant permanent follicles. In DUPA this assumption does not hold: grafts extracted from the donor zone may continue to miniaturise and eventually shed after transplantation, producing a result that degrades over time. DUPA can only be reliably identified by trichoscopy and dermoscopic follicle density mapping — clinical examination alone is insufficient. This is why we perform trichoscopy at every female consultation before issuing any graft estimate or treatment plan.

Is hair transplant safe after menopause?

Yes — post-menopausal androgenetic alopecia is one of the most common indications for female hair transplant. The drop in oestrogen after menopause shifts the hormonal balance toward relative androgen dominance, accelerating hair miniaturisation in genetically susceptible women. Provided the donor zone is healthy (no significant miniaturisation), the hair loss has been stable for 12+ months, and the general health criteria are met, post-menopausal women achieve hair transplant outcomes comparable to younger women. The pre-operative hormonal panel includes FSH + LH + oestradiol to characterise the post-menopausal hormonal profile. We are honest that transplanted hair in post-menopausal women may benefit from minoxidil continuation to maintain surrounding native hair density.

Can I be pregnant soon after a female hair transplant?

We recommend waiting at least 12 months after surgery before pregnancy. Two reasons: (1) the transplanted grafts need 12 to 18 months to reach their final growth phase — the dramatic hormonal shift of pregnancy triggers telogen effluvium (diffuse shedding) that can temporarily accelerate shock loss of both native and transplanted hair; (2) post-operative medications (minoxidil, spironolactone if prescribed) are contraindicated in pregnancy and breastfeeding. If you are planning pregnancy within 12 months, the consultation outcome may recommend deferring surgery until after you have completed your family. This is a clinical decision, not a marketing one — we make it based on your individual reproductive and health timeline.

What is the recovery process for female hair transplant?

Day 1 post-procedure: clinic wash with antiseptic solution, redness and mild oedema in the treated zones. Days 2 to 7: mild redness, occasional weeping, early crust formation — normal. Days 7 to 14: crusts shed (do not pick); donor area healing nearly complete. Weeks 2 to 8: shock loss — the transplanted grafts and surrounding native hair shed temporarily; this is the lowest point cosmetically and the most important phase to have pre-prepared for emotionally. Months 3 to 4: first fine new growth visible. Month 6: approximately 50 to 60 percent of the final density. Months 12 to 18: final result. Hair coordinator provides written and video aftercare instructions in your language before discharge. Any queries during recovery are answered within 24 hours.

How does female hair transplant compare with medical treatment (minoxidil, spironolactone)?

Medical treatment and hair transplant address different aspects of female hair loss. Minoxidil 2 to 5 percent topical and oral spironolactone are effective for slowing and partially reversing active hair loss in women — they are essential tools and the recommended first step when hair loss is recent, active or has an identifiable hormonal cause. However, medical therapy does not restore hair to zones that are already bald or severely thinned. Hair transplant permanently restores density in thinned zones by transferring DHT-resistant follicles. The clinically optimal approach for most FPHL patients is a combined strategy: medical therapy to stabilise the loss and protect existing native hair, followed by surgery to restore density in the most affected zones. We are honest in consultation about whether you are currently at the medical phase, the surgical phase, or the combined maintenance phase.

Why choose Eyeglow Health for female hair transplant?

At Eyeglow Health your female hair transplant is performed at our partner accredited hair restoration clinic in Istanbul. The operating surgeon is a partner specialist with documented FUE and DHI case volume; Eyeglow's named coordinator manages your journey from first consultation to 12-month photographic follow-up. We hold the Turkish Ministry of Health International Health Tourism Authority Certificate; our partner clinic holds the same certification. We are transparent that Eyeglow is an eye-care specialist clinic — hair restoration is delivered through our accredited partner clinic network with full disclosure. For female consultations specifically, we do not issue a graft estimate until the trichoscopy and hormonal blood panel results are reviewed. One in approximately four women who request a female hair transplant consultation at Eyeglow are directed toward medical optimisation first — not because it is commercially better for us, but because surgery on an unstabilised pattern produces inferior long-term outcomes.

What is the difference between Ludwig scale I, II and III for female hair loss?

The Ludwig classification (1977) is the standard descriptive scale for female pattern hair loss. Ludwig I: mild widening of the central part, increased visibility of the scalp on the crown, frontal hairline preserved. Ludwig II: more pronounced widening and thinning on the crown, frontal hairline still preserved; the widening part is visible from several feet away. Ludwig III: diffuse thinning across the entire crown with the frontal hairline largely or fully preserved; the scalp is clearly visible from the top. Hair transplant can restore density in Ludwig I, II and III with differing graft requirements (I: 1,000–1,800 grafts; II: 1,500–2,500 grafts; III: 2,000–3,500 grafts). Ludwig classification does not capture donor zone health, which is assessed separately by trichoscopy and is the critical variable in female candidacy.